Molecular epidemiology and antimicrobial resistance phenotype of paediatric bloodstream infections caused by Gram-negative bacteria in Oxfordshire, UK

Sam Lipworth[1,2], Karina-Doris Vihta[1,3], Tim Davies[1,2], Sarah Wright[2], Merline Tabirao[2], Kevin Chau[1], Alison Vaughan[1], James Kavanagh[1], Leanne Barker[1], Sophie George[1], Shelley Segal[2], Stephane Paulus[2], Lucinda Barrett[2], Sarah Oakley[2], Katie Jeffery[2], Lisa Butcher[2], Tim Peto[1,2,4,5], Derrick Crook[1,2,4,5], Sarah Walker[1,4,5], Seilesh Kadambari[2,6]* and Nicole Stoesser[1,2]*

*Joint Senior Authors

[1]Nuffield Department of Medicine, University of Oxford, UK

[2]Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[3]Department of Engineering, University of Oxford, UK

[4]NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with Public Health England, Oxford, United Kingdom

[5]NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

[6]Department of Paediatrics, University of Oxford, UK

Keywords: neonatal sepsis, paediatric bloodstream infections, whole genome sequencing, antimicrobial resistance

Running Title: Sequencing of paediatric Gram-negative sepsis

Corresponding author: Dr S Lipworth, Samuel.lipworth@ndm.ox.ac.uk

Alternate corresponding author: Dr N Stoesser Nicole.stoesser@ndm.ox.ac.uk

Abstract:

Objectives: Gram-negative organisms are common causes of bloodstream infection (BSI) during the neonatal period and early childhood. Whilst several large studies have characterised these isolates in adults, equivalent data (particularly incorporating whole genome sequencing) is lacking in the paediatric population.

Methods: We performed an epidemiological and sequencing based analysis of Gram-negative bloodstream infections in children <18 years old between 2008 and 2018 in Oxfordshire, UK.

Results: 327 isolates (296 successfully sequenced) from 287 patients were included. The burden of infection was predominantly in neonates (124/327[38%]). Most infections were caused by *Escherichia coli (149/327[46%])/Klebsiella* spp. (69/327[21%]) and *Enterobacter hormaechei (34/327[10%])*. There was no evidence of an increasing incidence of *E. coli* BSIs (IRRy 0.96, 95%CI 0.90-1.30, p=0.30) and for *Klebsiella* spp. there was some evidence that the incidence decreased slightly (IRRy 0.91, 95%CI 0.83-1.00, p=0.06). Similarly the proportion of antimicrobial resistant (across all antimicrobial classes evaluated) isolates did not change over time, though we did identify some evidence of sub-breakpoint increases in gentamicin resistance IRRy 1.86, 95%CI 1.33-2.58, $p_{heterogeneity}$=0.002. The population structure of *E. coli* BSI isolates in neonates and children mirrors that in adults with a predominance of STs 131/95/73/69 and the same proportion of O-antigen serotypes covered by the ExPEC-4V vaccine. In most cases there was no evidence of transmission/point-source acquisition and whole genome sequencing was able to refute a previously suspected *Serratia marcescens* outbreak.

Conclusion: Our findings support continued use of current empirical treatment guidelines and suggest that O-antigen targeted vaccines may have a role in reducing the incidence of neonatal sepsis.

47 **Introduction**

48 Gram-negative bloodstream infections (GNBSI) are a common cause of significant morbidity and
49 mortality globally in neonates and young children[1–4]. Their incidence has increased in both the UK
50 and US over the past decade, particularly in very low birth-weight neonates (VLBW, defined as
51 <1500g)[5,6]. Their association with antimicrobial resistance (AMR) has been highlighted by a recent
52 study in the United States of 721 *E. coli* isolates (including 393 bloodstream infection [BSI]-
53 associated isolates), which found high rates of non-susceptibility to commonly used empirical
54 antibiotics including ampicillin (66.8%) and gentamicin (16.8%), as well as an extended beta-
55 lactamase (ESBL) phenotype in 1 in 20 cases[7]. A recent study of 2,483 neonates with culture-
56 confirmed sepsis in low and middle-income countries showed that *Klebsiella* spp. was the
57 predominant pathogen causing multidrug-resistant neonatal sepsis[8]. In Greece, a retrospective
58 observational study in 16 neonatal intensive care units (NICUs) revealed almost half (45%; 36/80) of
59 *Klebsiella* spp. were resistant to either gentamicin or amikacin[9]. The ability of many Gram-negative
60 bacilli (GNB) to readily acquire and exchange genetic material (particularly AMR genes [ARGs]) via
61 mobile genetic elements means that the proliferation of drug-resistant strains remains a constant
62 threat.

63

64 The molecular epidemiology of *E. coli* and *Klebsiella* spp. isolates causing invasive infection in adults
65 has been characterised in large sequencing studies.[10,11] These have demonstrated the emergence of
66 particular AMR-associated sequence types (e.g. *E. coli* ST131), the genetic homogeneity of isolates
67 causing community and nosocomial onset infections suggesting a common reservoir, the potential
68 for vaccines to play a role in reducing the incidence of these infections, and the emerging threat of
69 the convergence of multidrug resistance and hypervirulence in *Klebsiella* spp. To our knowledge, no
70 study to date has systematically evaluated the molecular epidemiology of *E. coli*/*Klebsiella* spp. and
71 other common causes of GNBSI in a paediatric population; published studies focus predominantly on

evaluations of outbreaks caused by AMR-associated strains and/or on neonates (see above)[8,12,13]. In this study we therefore aimed to investigate sequencing data from a relatively large collection of sequentially acquired, unselected bloodstream isolates from neonates and children presenting to hospitals in Oxfordshire, UK, over the past decade.

Methods

Isolate selection

Oxford University Hospitals NHS Foundation Trust is a large healthcare provider in the South East of England serving a paediatric population of approximately 142,000 across four hospitals (of which two have emergency and acute general paediatric medicine, and one provides all neonatal/paediatric critical care and specialist paediatric services for the region). The microbiology laboratory additionally provides a service to all regional community healthcare providers. All *E. coli* and *Klebsiella* spp. isolates (deduplicated to one morphotype per 90-day period) from Oct-2008 to Nov-2018 collected from blood cultures of patients <18 years old on the day of collection were included in the study. The same selection criteria were applied to other GNB from August-2011 to September-2018. Prior to 2013 antimicrobial susceptibility testing was performed using disk diffusion; after this the Phoenix BD system was used with European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Amikacin susceptibility phenotyping was not routinely performed prior to 2013.

Sequencing procedures

Frozen stocks were sub-cultured onto Columbia blood agar and incubated overnight at 37°C. DNA extractions were performed using the QuickGene DNA extraction kit (Autogen, MA, USA) as per the manufacturer's instructions (with an additional mechanical lysis step – FastPrep, MP Biomedicals,

96 CA, USA; 6m/s for 40 secs, done twice). Sequencing was performed using Illumina HiSeq
97 2500/3000/4000/MiSeq instruments as described previously[14]. All sequencing data have been
98 deposited under NCBI accession number PRJNA604975.

99 **Bioinformatics**

100 *De novo* assembly was performed using Shovill (v1.0.4)[15]. Reads were mapped to sequence type
101 (ST[16,17]) specific references using Snippy (v4.6.0)[18] (Table S1). For the four *E. coli* STs with the largest
102 number of isolates (i.e. *E. coli* ST131/95/73/69), we created core genome alignments using Snippy-
103 core with the --mask auto setting, padded with the reference base at invariant positions; these
104 whole genome alignments were used as input to Gubbins (v 2.3.4)[19]. Such recombination-corrected
105 phylogenies were also created for *E.hormaechei* (the most common non-*E. coli*/*Klebsiella* species
106 detected in our study) and *S. marcescens* (because there was thought to have been an outbreak in
107 our neonatal ITU in 2016). We also used genomic distances calculated by Mash[20] (using -k21 -s
108 100,000 for within-study comparison of isolates and -k21 -s 1000 for comparison of isolates in this
109 study to our collection of sequences of adult bloodstream infection isolates[21] from the same region
110 over the same time period due to computational feasibility). Annotation against reference databases
111 (VFDB/ResFinder) was performed using ABRicate (v2.3.4)[22] with genes called as being present if
112 there was ≥80% coverage and DNA identity compared to the reference. Sequence types were
113 predicted using the MLST tool (v2.19)[23]. For *Klebsiella* spp. isolates speciation and virulence gene
114 detection (appendix) was performed using Kleborate (v2.0.4)[24].

115

116 **Definitions**

117 We defined isolates as being likely of neonatal origin if they originated from infants i) in their first 30
118 days of life, or were ii) on the neonatal intensive care unit, or iii) under the care of a neonatologist
119 on the day the blood culture was taken. For analytical purposes we classified other children as <12

120 months, 1-4 years, 5-9 years and 10-17 years of age. Early-onset infection was defined as disease
121 within the first 72 hours of life[25]. We calculated a 'resistance score' using a previously described
122 method[26] (the sum of the number of resistance gene categories carried out of amoxicillin, co-
123 trimoxazole, cefotaxime, gentamicin and ciprofloxacin). We further categorised BSIs according to
124 healthcare exposure prior to onset as follows: nosocomial (>48hours after admission to hospital),
125 'quasi-nosocomial' (within 30 days of last discharge), 'quasi-community' (31-365 days since last
126 discharge) and community (>365 days since last discharge)[27]. Genetic relatedness in the form of
127 single nucleotide polymorphism (SNP) thresholds definitively associated with transmission is variably
128 defined for the species evaluated; based on recent studies, we considered a threshold of >20 SNVs
129 between isolates as highly unlikely to be representative of a transmission event[28].

130

131 **Epidemiology/statistics**

132 Routinely collected healthcare data were acquired via pseudonymised linkage in the Infections in
133 Oxfordshire Research Database (IORD). IORD has generic Research Ethics Committee, Health
134 Research Authority and Confidentiality Advisory Group approvals (19/SC/0403, 19/CAG/0144) as a
135 de-identified electronic research database. Data on suspected infectious focus (only available for *E.*
136 *coli/Klebsiella* spp.) were acquired via linked local infection control records which had been
137 submitted to Public Health England as part of the mandatory surveillance programme. Likely source
138 was identified by infectious disease/microbiology physicians using best clinical judgement or
139 designated as unknown where there was significant uncertainty. For each species, we modelled the
140 number of bloodstream infections (BSIs) per year using negative binomial regression, with the total
141 number of paediatric admissions in each year used as an offset to account for changes in the
142 population over time. Only complete years (i.e. excluding 2008 and 2018) were included in this part
143 of the analysis. Median quantile regression was used to model the relationship between age and

144 virulence gene carriage/antimicrobial gene "resistance score"; this analysis was performed in STATA
145 version 15. All other statistical analysis was performed in R v4.0.3.

146

147 **Results**

148 **Microbiology of neonatal and paediatric Gram-negative bloodstream infections in Oxfordshire**

149 Of the 327 GNBSI isolates cultured during the study period from individuals aged <18 years, 149
150 (46%) were identified as *E. coli* and 69 (21%) as *Klebsiella* spp.; the remaining 109 (33%) belonged to
151 other species. There was no evidence of a change in the incidence of *E. coli* bloodstream infections
152 (BSIs) either overall (incidence rate ratio per year [i.e. the relative increase/decrease in incidence per
153 year] IRRy: 0.96, 95%CI: 0.90-1.03, p=0.30) or in neonates (IRRy: 0.97, 95%CI: 0.86-1.06, p=0.39). This
154 was also the case for other Gram-negative species both overall (IRRy: 1.07, 95%CI: 0.93-1.24, p=0.33)
155 and in the neonatal group (IRRy: 0.83, 95%CI: 0.65-1.07, p=0.19). Conversely there was some
156 evidence of a slight decrease in the overall number of *Klebsiella* spp. BSIs in the same period (overall
157 IRRy: 0.91, 95%CI 0.83-1.00, p=0.06; neonates IRRy: 0.80, 95%CI: 0.69-0.92, p=0.002).

158

159 Neonates had the highest number of GNBSI (124/327 [38%], of which 8 were early-onset) followed
160 by other infants <1y (66/327 [20%]) (Table 1). There were 62/327 (19%) cases in the 1st-4th years of
161 life, 28/327 (9%) in the 5th-9th and 47/327 (14%) in the 10th-17th. A higher proportion of isolates came
162 from males than would be expected from the birth:sex ratio (201/327 [61%], multinomial goodness
163 of fit p <0.001). BSIs in neonates, children aged 1-4 and 10-17 were predominantly nosocomial or
164 quasi-nosocomial whereas in those aged 3-12 months and 5-9 years they were predominantly
165 community or quasi-community onset (Table 1).

166

167 In our network of hospitals, amoxicillin and gentamicin are used as empirical treatment for neonatal
168 sepsis. In this patient group, 87/119 (73%) isolates were resistant to amoxicillin and 10/122 (8%) to
169 gentamicin (missing data for five and two isolates respectively); 7/118 (6%) isolates (4/56 *E. coli* and
170 3/27 *Klebsiella* spp.) were resistant to both. In older children (>1 month), ceftriaxone is the empirical
171 agent used in our setting and in this population 24/103 (13%) isolates were resistant (missing data
172 for 20 isolates). The proportion of resistant isolates appeared broadly stable over time (figure 1). For
173 gentamicin however, there was some evidence that proportion of susceptible isolates with an MIC
174 >1mg/L (IRRy 1.86, 95%CI 1.33-2.58) increased compared to those with an MIC <=1mg/L (IRRy 1.13,
175 95%CI 1.04-1.22) $p_{heterogeneity}$=0.002 (EUCAST gentamicin breakpoint for resistance >2mg/L). There
176 was no evidence of substantial differences in phenotypic profiles between treating specialties
177 (Figure S1). Similarly, the proportion of resistant isolates was similar for nosocomial vs. community-
178 onset cases for all agents except amoxicillin where nosocomial isolates were proportionally more
179 resistant (99/118 (84%) vs 115/174 (66%), table S1), reflecting the higher burden of non-*E. coli* BSIs
180 in this patient group (77/126 (61%) vs 101/201 (50%).

181

182 Data on likely primary infective focus was only available for 78 isolates (66 *E. coli*/12 *Klebsiella* spp.),
183 of these 18 (23%) were of gastrointestinal origin, 8 (10%) from invasive lines, 20 (26%) from the
184 urinary tract, 2 (3%) from the chest and 30 (38%) from unclear/other sources. Seventeen children
185 (six neonates) had infections with >1 species and five (two neonates) had polyclonal infections (>1 ST
186 of the same species).

187

188 **Molecular epidemiology of *Escherichia coli* causing BSI, including AMR and virulence gene burden**

189 Of the 146 *E. coli* isolates cultured, 133 (87%) were successfully sequenced (Figure 2). The four
190 dominant *E. coli* STs (ST131 n=16, ST95 n=16, ST73 n=20 and ST 69 n=15) were the same as those in

191 adults[21]. There was no evidence that the population structure observed differed from that in the
192 adult population in Oxfordshire (which is also the same as that observed globally[21]; multinomial
193 goodness of fit: p=0.44). The most prevalent O-antigen types were O6 (n=21), O1 (n=14), O2 (n=12),
194 O16 (n=10) and O25 (n=8). The proportion of isolates with an O-antigen included in the ExPEC-4V
195 vaccine[29,30] (which has been evaluated in a phase-II study in adults), was similar when comparing all
196 children (55/133, 41%) and neonates (25/53, 47%) to that seen in the overall population in our
197 previous study[31] (1499/3278 (46%); chi-squared: p=0.4 for both).

198

199 Carriage of genes conferring resistance to ampicillin was common (65/133, 49%), with bla_{TEM-1B}
200 (39/67, 58%) being the most prevalent allele. Eight isolates carried a gentamicin resistance gene (5
201 *aac(3)-IIa* [3 in ST131, 1 each in STs 73 and 23] and 3 *aac(3)-IId* [1 each in STs95 and 69]) and 20/133
202 (15%) carried a gene conferring resistance to ceftriaxone or cefotaxime (mostly ESBL genes, namely
203 $bla_{CTX-M-15}$ [n=9], $bla_{CTX-M-14b}$ [n=3] and $bla_{SHV-102}$ [n=5]); Figure 3). Whilst ST131 was the dominant ESBL-
204 gene-carrying ST (7/16, 44%), other STs carrying these genes included ST69 (2/15), ST73 (4/20),
205 ST2141 (3/3), ST12 (2/7) and STs 23 and 38 (1 each). Quantile regression revealed some association
206 between increasing age and increased resistance score (change in median per year, CMy=0.12, 95%
207 CI 0.04-0.19, p =0.002). Conversely there was some evidence that virulence gene carriage was higher
208 in younger children (CMy = -0.53 95%CI -1.03 - -0.033, p=0.04 Figure S2).

209

210 **Molecular epidemiology of *Klebsiella* spp. causing BSI, including AMR and virulence gene burden**

211 Of the 69 *Klebsiella* spp. isolates cultured, 60 (87%) were successfully sequenced. The predominant
212 *Klebsiella* spp. in both neonates and older infants/children was *Klebsiella pneumoniae* (n=28/60
213 [47%]), though a diverse selection of related species were also occasionally isolated (*K. oxytoca*:
214 n=12 [20%], *K. michiganensis*: n=8 (13%), *K. aerogenes*: 5 (8%), *K. grimontii*: n=3 (5%), *K.*

215 *ornithinolytica*: n=2 (3%) and *K. variicola*: n=2 (3%)). As we have previously observed in adults and in
216 contrast to the more clonal population seen in *E. coli*, STs causing *Klebsiella* spp. BSI were diverse
217 (n=32 STs in total). There were 11 isolates to which no ST could be assigned. We recently observed
218 that four O-antigens (O2v2, O1v1, O3b and O1v2) were found in 75% isolates from all *K. pneumoniae*
219 BSIs in Oxfordshire over a ten-year period; amongst paediatric BSIs this figure was 61% (17/28;
220 Fisher's exact test: p=0.15).

221

222 Half of *Klebsiella* spp. isolates (30/60) carried the yersiniabactin virulence factor (*ybt*); these were
223 mostly non-*K. pneumoniae* (12/12 *K. oxytoca*, 7/8 *K. michiganensis*, 2/2 *K. ornitholytica* and 3/3 *K.*
224 *grimontii*). One *K. aerogenes* isolate additionally carried the genotoxin colibactin (*clb*). There was no
225 difference in the proportion of E. coli/Klebsiella spp. isolates carrying a gene conferring ceftriaxone
226 resistance (19/137, 14% vs 9/66, 14%, p=0.99). Only 4/60 (7%) isolates carried a gentamicin
227 resistance gene (four *aac(3)-IIa* and one *aac(3)-Ia*, similar to *E. coli* (8/133, 6%); Fisher's exact test:
228 p=0.90).

229

230 **Other Gram-negative species**

231 Of the 104 non-*E. coli*/*Klebsiella* spp. ("other") GNB cultured in this study, 77 (74%) were successfully
232 sequenced. The predominant species in both neonates and older children was *E. hormaechei*
233 (overall: 34/75, [44%]; neonatal: 14/25 [56%]). This was also the only other species carrying ESBL-
234 producing genes ($bla_{CTX\text{-}M\text{-}15}$ in four isolates, Figure 3); these isolates also carried the $bla_{TEM\text{-}1B}$ beta-
235 lactamase as well as *aac(3)-IIa* conferring gentamicin resistance. Two isolates carrying class-D beta-
236 lactamases predicted to confer carbapenem resistance were identified ($bla_{OXA\text{-}23}$ in *Acinetobacter*
237 *baumannii*, $bla_{OXA\text{-}427}$ in *Aeromonas caviae*).

238

239 **Genomic relatedness of isolates**

240 Analysis of recombination-corrected phylogenies for the major *E. coli* STs (131/95/69) demonstrated
241 no clear evidence of direct or temporally related indirect transmission between patients (with the
242 closest genomic distance between patients = 32/87/28 single nucleotide variants [SNV] for
243 ST131/95/69 respectively). There was a cluster of three near-identical ST73 isolates from two
244 patients (3/6 SNPs apart), however the isolation date was ~2 years apart and these patients had
245 never been admitted to hospital at the same time. There was a cluster of three multidrug-resistant
246 *E. hormaechei* isolates separated by a maximum of 37 SNPs. All three patients had been admitted in
247 the same year but not at the same time and to different wards. Other *E. hormaechei* isolates were
248 genomically diverse (Figure 4). Three *S. marcescens* from the neonatal ICU in 20116 were grouped
249 together in the phylogeny (Figure S3) however the relatively large distances between them
250 (31/81/85 SNPs), made recent transmission unlikely.

251

252 There was no difference in the distributions of genomic distances (reflected here by Mash distances)
253 between isolates from patients admitted i) in the same year, ii) to the same ward in the same year,
254 or iii) to the same ward with overlapping admission dates and iv) overall (i.e. all admissions to any
255 ward at any time point) (Kruskal-Wallis rank sum test p=0.30, Figure S4). Finally, when considering *E.*
256 *coli* and *Klebsiella* isolates in this study, there was no difference between the Mash distances to the
257 nearest paediatric genomic neighbour (median: 0.00093 [IQR: 0.00036-0.0023]) compared to the
258 nearest adult neighbour (median: 0.0011 [IQR: 0.00041-0.0024], Wilcoxon rank sum p=0.33. Figure
259 S5).

260

261 **Discussion**

262 *E. coli* was the main causative agent of paediatric and neonatal Gram-negative bloodstream infection
263 in our study over a ten year period. The population structure of *E. coli* isolates causing invasive
264 infection in children mirrors that seen in our centre and globally for adults. We found no evidence of
265 significant nosocomial transmission suggesting that in our setting invasive isolates are acquired from
266 the environment or as a result of colonisation from parents/other close contacts. Our findings
267 suggest O-antigen targeted vaccines (currently in phase II/III trials in adults) might have the potential
268 to reduce the incidence of invasive neonatal and paediatric *E. coli* infections, in the former
269 potentially by immunisation of pregnant women. Most isolates remained susceptible to at least one
270 first-line antibiotic justifying continuation of current empirical treatment guidelines which should
271 include an aminoglycoside in neonates[25]. There was however some evidence of increasing (sub-
272 breakpoint) gentamicin MIC which warrants ongoing surveillance, and 1 in 20 GNBSIs were caused
273 by isolates resistant to the ampicillin+gentamicin combination.

274

275 The incidence of these infections has remained stable over the past decade in children, in contrast to
276 the increase observed in adults. The substantial burden of disease due to paediatric GNBSI occurs in
277 neonates. The absence of evidence of an increasing burden of AMR-associated disease and
278 demonstrable outbreaks likely points to good infection control practice and antimicrobial
279 stewardship, and in our setting we were able to replicate results from a previous study[26] suggesting
280 greater carriage of virulence genes in *E. coli* isolates from younger children and neonates but higher
281 resistance scores in older children. Continued epidemiological surveillance with targeted whole
282 genome sequencing to identify strain and/or plasmid outbreaks may help to inform early infection
283 control interventions and would seem particularly justified in these age groups given the high
284 associated morbidity and mortality. In addition we would encourage consideration of clinical trials of
285 existing O-antigen targeted vaccines for prevention of neonatal sepsis.

286

287 Our data suggest that rates of infection with non-*E. coli/Klebsiella* spp. (in particular *E. hormachei)*
288 are higher in the neonatal and paediatric settings than in adults. These results highlight the
289 importance of this pathogen as a potential causative agent of neonatal and paediatric sepsis as well
290 as its potential to cause multidrug-resistant outbreaks in this setting. Several small clusters of *E.*
291 *hormaechei* (part of the *E. cloacae* complex) bloodstream infection in neonates have been described
292 in the literature, with enteral feeding and milk formulations as well as poor general infection control
293 procedures thought to be implicated[32–34].

294

295 Our data highlights the value of whole genome sequencing for the investigation of potential
296 outbreaks on neonatal units. WGS analysis of three isolates from a suspected (on the basis of
297 epidemiology and pulsed-field gel electrophoresis) *S. marcescens* outbreak suggested recent
298 transmission was actually highly unlikely. Had this analysis been performed in real-time it may have
299 reassured clinicians and saved time and resource. Apart from a small cluster of three patients with *E.*
300 *hormaechei* infections where acquisition from a common source was possible based on genomic and
301 epidemiological analysis (though the patients were never admitted to the same ward), there was
302 relatively high diversity amongst isolates effectively ruling out transmission/point-source acquisition
303 resulting in BSI. However, unwell neonates are often transferred across a geographic region for
304 specialist care and so it is essential that active surveillance mechanisms (collecting and analysing
305 real-time microbiological data) are implemented across networks in order to inform infection
306 prevention measures appropriately.

307

308 Notably, whilst we found a lack of clear evidence of transmission between patients in this study, BSIs
309 are likely to represent an extremely insensitive marker of transmission events, as most transmission
310 with these organisms would be expected to lead to colonisation and not necessarily invasive
311 infection. Furthermore whilst the short-read sequencing used in this study allows us to confidently

312 exclude outbreaks of strains, we cannot address the question of potential transmission of AMR
313 genes and virulence factors on plasmids. Additional limitations include the fact that we were not
314 able to sequence all cultured isolates, the relatively sparse availability of data on source attribution
315 and the single region nature of the study. We did not sample other reservoirs potentially
316 contributing to transmission, including the unit environment.

317

318 In summary, our study highlights a relative success story of a flat overall incidence trend and stable
319 numbers of AMR-carrying GNBSI isolates in children, contrasting with what has been seen in adult
320 populations in the same setting[21]. Pertinently our data supports the ongoing use of an
321 aminoglycoside as part of empirical treatment guidelines in neonatal sepsis. The disproportionate
322 impact of GNBSI on neonates and young infants should encourage active microbiological surveillance
323 across neonatal networks and strategies to prevent disease through vaccine trials in pregnant
324 women.

325

326

327 **Figure legends**

328 Figure 1 – Change in minimum inhibitory concentrations (MIC) of isolates over time.

329 Figure 2 - Species (and sequence type, ST, where shown) for sequenced isolate over time. Each
330 point represents the isolation date of a sequenced isolate. The grey shaded area represents the fact
331 that sequencing of non-*E. coli*/*Klebsiella* spp. isolates did not begin prior to 2012.

332 Figure 3 – Carriage of antimicrobial resistance genes by isolates sequenced in the study. The tree
333 was created using mashtree and gene presence is shown in red. The black/green/maroon/orange
334 bars at the top represent carriage of genes producing enzymes with activity against
335 aminoglycosides/amoxicillin/cefotaxime/ceftriaxone respectively.

336

337 Figure 4 – Recombination corrected phylogeny of *Enterobacter hormaechei* isolates sequenced in
338 this study. Tree tip colours show the year of isolates, red bars denote presence/absence of
339 antimicrobial resistance genes. The scale of the tree is shown in SNPs.

340

341 **Table legend**

342 Table 1 – microbiological and patient characteristics of patients with Gram-negative bloodstream
343 infections in Oxfordshire stratified by age of onset. P values represent Fisher exact tests for
344 categorical and Kruskal-Wallis tests for continuous variables.

345

346 **Ethics Statement**

347 The Infections in Oxfordshire Research Database (IORD; https://oxfordbrc.nihr.ac.uk/research-
348 themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-
349 research-database-iord/) has generic Research Ethics Committee, Health Research Authority and
350 Confidentiality Advisory Group approvals (19/SC/0403, 19/CAG/0144) which facilitate the pseudo-
351 anonymised linkage of routinely collected NHS electronic healthcare record data from the Oxford
352 University Hospitals NHS Foundation Trust Clinical Systems Data Warehouse and research data (e.g.
353 sequencing data) from the Antimicrobial Resistance and Modernising Microbiology Theme of the
354 Oxford NIHR Biomedical Research Centre, Oxford. IORD links records by a specific, random, number
355 ensuring that no patient-identifiable information is shared with researchers using this resource. We
356 sequenced bacterial isolates from bloodstream infections that are routinely stored by the John
357 Radcliffe Hospital Microbiology laboratory. In the UK, bacterial isolates (such as those sequenced in
358 this study) routinely cultured from human clinical samples do not require ethical approval for

359 analysis under the provisions of the Human Tissue Act as they do not contain any material
360 considered to be human tissue.

361

362 **References**

363 1. Malande OO, Nuttall J, Pillay V, Bamford C, Eley B. A ten-year review of ESBL and non-ESBL
364 Escherichia coli bloodstream infections among children at a tertiary referral hospital in South
365 Africa. *PLoS One*. 2019;14(9):e0222675.

366 2. Powell EC, Mahajan PV, Roosevelt G, et al. Epidemiology of Bacteremia in Febrile Infants Aged
367 60 Days and Younger. *Ann Emerg Med*. 2018;71(2):211-216.

368 3. Shakur SM, Whitehall J, Mudgil P. Pediatric bloodstream infections in metropolitan Australia.
369 *World J Pediatr*. 2019;15(2):161-167.

370 4. Agyeman PKA, Schlapbach LJ, Giannoni E, et al. Epidemiology of blood culture-proven bacterial
371 sepsis in children in Switzerland: a population-based cohort study. *Lancet Child Adolesc Health*.
372 2017;1(2):124-133.

373 5. Stoll BJ, Puopolo KM, Hansen NI, et al. Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of
374 Escherichia coli, and the Need for Novel Prevention Strategies. *JAMA Pediatr*.
375 2020;174(7):e200593.

376 6. *Annual Publication of Epidemiological Commentary*. Public Health England; 2020.
377 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat
378 a/file/940716/Annual_epidemiology_commentary_April_2019_March_2020.pdf

379 7. Flannery DD, Akinboyo IC, Mukhopadhyay S, et al. Antibiotic Susceptibility of Escherichia coli
380 Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017.
381 *JAMA Pediatr*. 2021;175(2):168-175.

382 8. Sands K, Carvalho MJ, Portal E, et al. Characterization of antimicrobial-resistant Gram-negative
383 bacteria that cause neonatal sepsis in seven low- and middle-income countries. *Nat Microbiol*.
384 2021;6(4):512-523.

385 9. Gkentzi D, Kortsalioudaki C, Cailes BC, et al. Epidemiology of infections and antimicrobial use in
386 Greek Neonatal Units. *Arch Dis Child Fetal Neonatal Ed*. 2019;104(3):F293-F297.

387 10. Kallonen T, Brodrick HJ, Harris SR, et al. Systematic longitudinal survey of invasive Escherichia
388 coli in England demonstrates a stable population structure only transiently disturbed by the
389 emergence of ST131. *Genome Res*. Published online July 18, 2017. doi:10.1101/gr.216606.116

390 11. Ellington MJ, Heinz E, Wailan AM, et al. Contrasting patterns of longitudinal population
391 dynamics and antimicrobial resistance mechanisms in two priority bacterial pathogens over 7
392 years in a single center. *Genome Biol*. 2019;20(1):184.

393 12. Giuffrè M, Cipolla D, Bonura C, et al. Outbreak of colonizations by extended-spectrum β-
394 lactamase-producing Escherichia coli sequence type 131 in a neonatal intensive care unit, Italy.
395 *Antimicrob Resist Infect Control*. 2013;2(1):8.

396 13. Stoesser N, Giess A, Batty EM, et al. Genome sequencing of an extended series of NDM-
397 producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital
398 characterizes the extent of community- versus hospital-associated transmission in an endemic
399 setting. *Antimicrob Agents Chemother*. 2014;58(12):7347-7357.

400 14. De Maio N, Shaw LP, Hubbard A, et al. Comparison of long-read sequencing technologies in the
401 hybrid assembly of complex bacterial genomes. *Microb Genom*. 2019;5(9).
402 doi:10.1099/mgen.0.000294

403 15. Seemann T. Shovill. Accessed May 18, 2020. https://github.com/tseemann/shovill

404 16. Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective.
405 *Mol Microbiol*. 2006;60(5):1136-1151.

406 17. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. Multilocus sequence typing of Klebsiella
407 pneumoniae nosocomial isolates. *J Clin Microbiol*. 2005;43(8):4178-4182.

408 18. Seemann T. *Snippy*. Github; 2015. Accessed September 12, 2017.
409 https://github.com/tseemann/snippy

410 19. Croucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of
411 recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res*.
412 2015;43(3):e15.

413 20. Ondov BD, Treangen TJ, Melsted P, et al. Mash: fast genome and metagenome distance
414 estimation using MinHash. *Genome Biol*. 2016;17(1):132.

415 21. Lipworth S, Vihta K-D, Chau K, et al. Molecular epidemiology of Escherichia coli and Klebsiella
416 species bloodstream infections in Oxfordshire (UK) 2008-2018. *medRxiv*. Published online 2021.

417 22. Seemann T. *Abricate*. Github Accessed July 5, 2019. https://github.com/tseemann/abricate

418 23. Seemann T. *Mlst*. Github Accessed July 12, 2019. https://github.com/tseemann/mlst

419 24. Holt K. Kleborate. Accessed May 22, 2020. https://github.com/katholt/Kleborate

420 25. *Neonatal Infection: Antibiotics for Prevention and Treatment*. National Institute for Clinical
421 Excellence Accessed May 4, 2021. https://www.nice.org.uk/guidance/ng195

422 26. Burdet C, Clermont O, Bonacorsi S, et al. Escherichia coli bacteremia in children: age and portal
423 of entry are the main predictors of severity. *Pediatr Infect Dis J*. 2014;33(8):872-879.

424 27. Vihta K-D, Stoesser N, Llewelyn MJ, et al. Trends over time in Escherichia coli bloodstream
425 infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016:
426 a study of electronic health records. *Lancet Infect Dis*. 2018;18(10):1138-1149.

427 28. Wyres KL, Hawkey J, Mirčeta M, et al. Genomic surveillance of antimicrobial resistant bacterial
428 colonisation and infection in intensive care patients. *BMC Infect Dis*. 2021;21(1):683.

429 29. Frenck RW Jr, Ervin J, Chu L, et al. Safety and immunogenicity of a vaccine for extra-intestinal
430 pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. *Lancet Infect Dis*.
431 2019;19(6):631-640.

432 30. Huttner A, Gambillara V. The development and early clinical testing of the ExPEC4V conjugate
433 vaccine against uropathogenic Escherichia coli. *Clin Microbiol Infect*. 2018;24(10):1046-1050.

434 31. Lipworth S, Vihta K-D, Chau KK, et al. Ten years of population-level genomic Escherichia coli and
435 Klebsiella pneumoniae serotype surveillance informs vaccine development for invasive
436 infections. *Clin Infect Dis*. Published online January 7, 2021. doi:10.1093/cid/ciab006

437 32. Giammanco GM, Aleo A, Guida I, Mammina C. Molecular epidemiological survey of Citrobacter
438 freundii misidentified as Cronobacter spp. (Enterobacter sakazakii) and Enterobacter
439 hormaechei isolated from powdered infant milk formula. *Foodborne Pathog Dis*. 2011;8(4):517-
440 525.

441 33. El-Zamkan MA, Mohamed HMA. Molecular detection ofEnterobacterspp. and other related
442 species in powdered milk infant formula and milk powder. *J Food Saf*. 2018;38(6):e12538.

443 34. da Silva CLP, Miranda LEV, Moreira BM, et al. Enterobacter hormaechei bloodstream infection
444 at three neonatal intensive care units in Brazil. *Pediatr Infect Dis J*. 2002;21(2):175-177.


E. coli other
E. coli ST131
E. coli ST95
E. coli ST12
E. coli ST127
E. coli ST69
E. coli ST73
Klebsiella aerogenes
Klebsiella varticola
Klebsiella pneumoniae
Klebsiella ornithinolytica
Klebsiella oxytoca
Klebsiella grimontii
Klebsiella michiganensis
Enterobacter hormaechei
Enterobacter ludwigii
Enterobacter asburiae
Enterobacter roggenkampii
Pseudomonas spp.
Pseudomonas aeruginosa
Citrobacter sedlakii
Citrobacter youngae
Citrobacter freundii
Citrobacter braakii
Citrobacter koseri
Pantoea brenneri
Serratia marcescens
Proteus mirabilis
Aeromonas caviae
Stenotrophomonas maltophilia
Acinetobacter parvus
Acinetobacter ursingii
Acinetobacter lwoffii
Acinetobacter spp.
Acinetobacter baumannii
Species
2010
2012
2014
2016
2018
Collection Date


Ampicillin
E. coli
Klebsiella spp.
Other
n
year
MIC
<=2
4
8
>8
Ceftriaxone
MIC
<=1
2
>4
Gentamicin
MIC
<=1
2
4
>4
Ciprofloxacin
MIC
<=0.5
<=1
>1
Piperacillin Tazobactam
MIC
<=4/4
8/4
16/4
>16/4
>64/4
Amikacin
MIC
<=4
8
16
>16



aac(3)-Ild
aac(3)-Ila
aemA
blaTEM-1D
blaSED-1
blaTEM-1B
blaTEM-1C
blaTEM-33
blaTEM-30
blaTEM-1A
blaLEN-1
blaLEN-2
blaOXA-1
blaOXA-2
blaOXA-427
blaTEM-1A
blaTEM-122
blaSHV-1
blaSHV-16
blaSHV-33
blaSHV-2
blaCAC-1
blaCAC-2
blaACT-12
blaACT-14
blaACT-7
blaSHV-25
blaOXA-15
blaOXA-18
blaOXA-4
blaOXA-6-4
blaOXA-9
blaOXA-13
blaOXA-1
blaACT-5
blaCAC-1
blaCAC-2
blaCMY-65
blaCMY-2
blaCMY-58
blaCMY-69
blaCMY-2
blaCMY-16
blaCMY-7
blaCMY-8
blaCMY-15
blaCMY-4
blaCMY-4b
blaCMY-42
blaSHV-12
blaSHV-27
blaSHV-12
blaSHV-106
Species/MLST
Acinetobacter
Aeromonas
Citrobacter
E. coli
E. coli ST12
E. coli ST127
E. coli ST131
E. coli ST69
E. coli ST73
E. coli ST95
Enterobacter
Klebsiella
Pantoea
Proteus
Serratia
Stenotrophomonas


13105
aac(3)-IIa
aac(6')-Ib-cr
aadA2
ant(3'')-Ia
aph(3'')-Ib
aph(6)-Id
blaACT-14
blaACT-15
blaACT-16
blaACT-5
blaACT-7
blaCTX-M-15
blaOXA-1
blaTEM-1B
catA1
dfrA14
fosA
mcr-9
mdf(A)
oqxA
oqxB
qnrB1
sul1
sul2
tet(A)
Year
2012
2013
2014
2015
2016
2017
2018

		Neonatal Early Onset	**Neonatal Late Onset**	**<12 months**	**1-4 years**	**5-9 years**	**10-17 years**	**p**
Species (%)	*Acinetobacter* spp.	1 (12.5)	3 (2.6)	6 (9.1)	9 (14.5)	4 (14.3)	4 (8.5)	<0.001
	E. coli	6 (75.0)	51 (44.0)	42 (63.6)	17 (27.4)	6 (21.4)	27 (57.4)	
	Enterobacter spp.	1 (12.5)	24 (20.7)	8 (12.1)	13 (21.0)	5 (17.9)	4 (8.5)	
	Citrobacter spp.		2 (1.7)		2 (3.2)	3 (10.7)	1 (2.1)	
	Klebsiella spp.		28 (24.1)	10 (15.2)	16 (25.8)	6 (21.4)	9 (19.1)	
	Serratia spp.		8 (6.9)				1 (2.1)	
	Aeromonas spp.				3 (4.8)	1 (3.6)		
	Proteus spp.				2 (3.2)			
	Pantoea spp.					3 (10.7)	1 (2.1)	
Age	Median (IQR)	0.0 (0.0 to 1.2)	20.0 (11.8 to 49.2)	91.0 (57.5 to 177.5)	689.0 (512.2 to 969.8)	1893.0 (1770.0 to 2346.2)	5391.0 (3992.5 to 6168.5)	<0.001
Sex (%)	Female	4 (50.0)	38 (32.8)	28 (42.4)	28 (45.2)	9 (32.1)	19 (40.4)	0.51
	Male	4 (50.0)	78 (67.2)	38 (57.6)	34 (54.8)	19 (67.9)	28 (59.6)	

		Neonatal Early Onset	**Neonatal Late Onset**	**<12 months**	**1-4 years**	**5-9 years**	**10-17 years**	**p**
Specimen (%) Category	Nosocomial	0 (0.0)	86 (74.1)	7 (10.6)	18 (29.0)	0 (0.0)	15 (31.9)	<0.001
	Healthcare associated 0-30d	2 (25.0)	15 (12.9)	8 (12.1)	21 (33.9)	13 (46.4)	16 (34.0)	
	Healthcare associated 31-365d	0 (0.0)	3 (2.6)	29 (43.9)	11 (17.7)	4 (14.3)	5 (10.6)	
	Community	6 (75.0)	12 (10.3)	22 (33.3)	12 (19.4)	11 (39.3)	11 (23.4)	
Admission Length	Median (IQR)	14.2 (9.9 to 27.5)	51.7 (20.8 to 129.7)	4.1 (2.5 to 7.9)	8.8 (2.5 to 30.6)	3.1 (2.1 to 7.8)	5.5 (2.9 to 28.0)	<0.001
Death Within 30 Days (%)	No	6 (75.0)	86 (76.1)	44 (67.7)	52 (83.9)	21 (75.0)	39 (83.0)	0.30
	Yes	2 (25.0)	27 (23.9)	21 (32.3)	10 (16.1)	7 (25.0)	8 (17.0)	
CRP	Median (IQR)	8.2 (0.6 to 37.9)	64.1 (16.1 to 150.3)	99.2 (45.5 to 125.0)	50.1 (10.1 to 122.2)	16.7 (5.0 to 56.8)	59.2 (13.9 to 118.4)	0.08
Creatinine	Median (IQR)	61.0 (55.0 to 78.0)	37.0 (23.0 to 60.8)	24.0 (18.0 to 28.0)	22.0 (16.0 to 32.0)	36.0 (28.0 to 41.0)	55.5 (45.0 to 66.5)	<0.001

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
Neutrophils	Median (IQR)	2.9 (1.9 to 10.1)	5.9 (3.1 to 9.8)	9.3 (5.4 to 15.0)	5.5 (2.7 to 11.3)	3.5 (1.9 to 7.2)	4.6 (0.1 to 8.4)	0.004
Amoxicillin	S	5 (71.4)	27 (24.1)	25 (42.4)	11 (22.0)	5 (20.8)	5 (12.5)	0.002
(missing=35)	R	2 (28.6)	85 (75.9)	34 (57.6)	39 (78.0)	19 (79.2)	35 (87.5)	
Ceftriaxone	S	6 (85.7)	96 (85.0)	57 (93.4)	43 (81.1)	23 (85.2)	36 (85.7)	0.46
(missing=24)	R	1 (14.3)	17 (15.0)	4 (6.6)	10 (18.9)	4 (14.8)	6 (14.3)	
Meropenem	S	8 (100.0)	115 (100.0)	62 (100.0)	61 (100.0)	28 (100.0)	43 (97.7)	0.26
(missing=9)	R	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.3)	
Ciprofloxacin	S	7 (87.5)	110 (95.7)	62 (100.0)	55 (91.7)	27 (96.4)	39 (88.6)	0.05
(missing=10)	R	1 (12.5)	5 (4.3)	0 (0.0)	5 (8.3)	1 (3.6)	5 (11.4)	
Amikacin	S	3 (100.0)	47 (90.4)	15 (100.0)	21 (87.5)	17 (100.0)	21 (91.3)	0.63
(missing=193)	R	0 (0.0)	5 (9.6)	0 (0.0)	3 (12.5)	0 (0.0)	2 (8.7)	
Gentamicin	S	7 (87.5)	105 (92.1)	60 (96.8)	53 (86.9)	25 (92.6)	38 (86.4)	0.27

		Neonatal Early Onset	Neonatal Late Onset	<12 months	1-4 years	5-9 years	10-17 years	p
(missing=11)	R	1 (12.5)	9 (7.9)	2 (3.2)	8 (13.1)	2 (7.4)	6 (13.6)	
Piperacillin-Tazobactam	S	8 (100.0)	105 (92.1)	56 (93.3)	48 (85.7)	23 (88.5)	37 (86.0)	0.57
(missing=20)	R		9 (7.9)	4 (6.7)	8 (14.3)	3 (11.5)	6 (14.0)	
Fosfomycin	S	1 (100.0)	45 (93.8)	10 (90.9)	14 (87.5)	11 (84.6)	18 (94.7)	0.72
(missing=219)	R		3 (6.2)	1 (9.1)	2 (12.5)	2 (15.4)	1 (5.3)	